Parent Company Med-Life Discoveries receives MJFF Grant

GraySpace Therapeutics’ parent company Med-Life Discoveries (MLD) has recently been awarded a “Spring 2020 Use of Parkinson’s Disease Biosamples” grant from The Michael J Fox Foundation for Parkinson’s Research (MJFF).

“This grant will provide a deeper look into the role of plasmalogens in the development and progression of Parkinson’s disease,” says Dr. Shawn Ritchie, CEO of MLD and COO and CSO of GraySpace Therapeutics. “With GraySpace focused solely on the development of MLD’s plasmalogen-based therapeutic technology for both Alzheimer’s and Parkinson’s disease, we are excited to have this rare opportunity to better understand how plasmalogen deficiency drives Parkinson’s disease progression and treatment response in a highly characterized patient population.”

MLD is the parent company and current primary shareholder of GraySpace Therapeutics.